Hit enter to search or ESC to close
YOZMA GROUP KOREAYOZMA GROUP KOREA
Menu
  • About
    • Overview
    • Our Team
  • Business
    • Investment
    • Accelerator
    • Consulting
    • Tech Transfer
  • Campus
    • Overview
    • Partners
    • Portfolio
  • Portfolio
  • Newsroom
    • News
    • Press Release
    • Video
  • Contact
    • Recruit
  • English
    • Korean
  • About
    • Overview
    • Our Team
  • Business
    • Investment
    • Accelerator
    • Consulting
    • Tech Transfer
  • Campus
    • Overview
    • Partners
    • Portfolio
  • Portfolio
  • Newsroom
    • News
    • Press Release
    • Video
  • Contact
    • Recruit
  • English
    • Korean
Syntekabio recieves patent for AI cancer antigens predicting platform
News

Syntekabio recieves patent for AI cancer antigens predicting platform

By 관리정경단2022-06-27No Comments

Home » Syntekabio recieves patent for AI cancer antigens predicting platform

Syntekabio recieves patent for AI cancer antigens predicting platform

https://www.hankyung.com/it/article/202206201353i
  • Previous PostIngradient-DDCares promote joint research on AI for pets

  • Next Post"Increasing cyber attack on private companies... Industrial security is national security"

Seoul Office
9F, 457, Bongeunsa-ro, Gangnam-gu, Seoul, Republic of Korea
t. +82 2 6949 5350
e. [email protected]

Israel Office
2 Ben Gurion way, BSR 1 building fl 14, Ramat Gan, Israel
e. [email protected]

Family Site →
  • Privacy Policy

© 2025 Yozma Group Korea.